Seeking Alpha

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

The last time I wrote about 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In ...
Nasdaq

4D Molecular Therapeutics Accelerates Phase 3 Trial Timelines for 4D-150 in Wet AMD and Streamlines Operations

4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...
Seeking Alpha

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

4D Molecular Therapeutics (NASDAQ:FDMT) has several clinical programs in its pipeline, with one of them being 4D-710 being advanced for the treatment of patients with Cystic Fibrosis [CF]. The most ...
WDAF-TV

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular ...
FierceBiotech

Astellas paves backloaded biobucks deal to test 4DMT's eye disease gene therapy vector

Astellas Pharma is digging up some cash to use one of 4D Molecular Therapeutics’ gene therapy vectors for at least one rare eye disease—but the genetic medicines company is going to have to wait a ...
Healio

Astellas, 4D Molecular Therapeutics enter license agreement for retinotopic vector

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...